Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) FCF Margin (2021 - 2025)

Oncology Institute (TOI) has disclosed FCF Margin for 5 consecutive years, with 9.69% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 1091.0% year-over-year to 9.69%, compared with a TTM value of 5.97% through Sep 2025, up 393.0%, and an annual FY2024 reading of 7.71%, up 490.0% over the prior year.
  • FCF Margin was 9.69% for Q3 2025 at Oncology Institute, down from 9.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 2.42% in Q4 2024 and bottomed at 46.28% in Q4 2021.
  • Average FCF Margin over 5 years is 14.51%, with a median of 11.96% recorded in 2023.
  • Peak annual rise in FCF Margin hit 3163bps in 2022, while the deepest fall reached -3228bps in 2022.
  • Year by year, FCF Margin stood at 46.28% in 2021, then surged by 68bps to 14.65% in 2022, then skyrocketed by 62bps to 5.54% in 2023, then soared by 144bps to 2.42% in 2024, then tumbled by -500bps to 9.69% in 2025.
  • Business Quant data shows FCF Margin for TOI at 9.69% in Q3 2025, 9.52% in Q2 2025, and 5.09% in Q1 2025.